Project Grant F30CA310469
Award Date 12/1/26
Completion Date 6/30/29
Dollars Obligated $105K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $155,052 on January 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research dissecting the role of focal adhesion kinase (FAK) in modulating immunity during metastatic reactivation and progression. The research integrates in vivo genetic perturbation screening with RNA-sequencing analysis to investigate how FAK promotes metastatic reactivation and immune evasion by...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $712,912 for research into the functional determinants of disseminated tumor cell dormancy in the brain under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2026. The recipient will conduct a five-year project through July 31, 2031 to explore how breast cancer cells reshape the brain microenvironment to establish and maintain a dormancy-supportive niche. The research centers on the role of...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded Health Research, Inc. (Roswell Park Division) $446,112 on July 3, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify age-regulating breast cancer dormancy genes using C. elegans dauer models. The project investigates how chronological aging of dormant cancer cells drives metastatic relapse and reawakening after initial treatment. The recipient...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $155,052 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to conduct spatiotemporal resolution of niche and genomic co-evolution in brain-metastatic organotropism. The funded research develops pre-clinical models and conducts multi-modal single-cell and spatial genomics analyses to investigate the relationship between chromosomal instability and brain metastasis...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded a cooperative agreement totaling $681,310 to The Trustees of Columbia University in the City of New York on June 24, 2026, under the Cancer Biology Research program (CFDA 93.396). The funded research investigates mechanisms that promote bone metastasis in prostate cancer, the major cause of death in metastatic prostate cancer patients. Columbia will use genetically-engineered mouse models (GEMMs) to...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $681,818 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research into restoring anti-tumor immunity in chromosomally unstable tumors. The research addresses chromosomal instability (CIN)—frequent chromosome missegregation during mitosis—as a genomic hallmark of solid tumors that correlates with immune evasion and resistance to immunotherapies. The project...
- The National Cancer Institute, under the Department of Health and Human Services National Institutes of Health, awarded The Trustees of Columbia University in the City of New York $630,089 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The award funds research to characterize the molecular mechanisms by which the DNA translocase SMARCAL1 suppresses anti-tumor immune responses and to identify other DNA damage response factors that function analogously to...
- The National Institutes of Health National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $827,111 on July 21, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of the proline hydroxylase P4HA2 in metastatic tumor dormancy and the dormancy-to-reactivation transition. The project examines how dormant disseminated tumor cells regulate collagen extracellular matrix formation through control of proline hydroxylation, hypothesizing that P4HA2...
- The National Cancer Institute awarded Albert Einstein College of Medicine $168,000 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate dormancy and recurrence mechanisms in pancreatic ductal adenocarcinoma. The research examines how disseminated tumor cells in pancreatic cancer patients enter a dormant state, allowing minimal residual disease to persist after surgery and chemotherapy despite high initial response rates. The project focuses on two...
- The National Cancer Institute awarded $433,759 to Trustees of Tufts College (doing business as Tufts University School of Medicine) on June 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms by which dormant prostate cancer cells in bone marrow are reactivated into proliferation. The research focuses on osteoclastic tunneling nanotubes (TNTs)—membranous conduits that facilitate intercellular transfer of molecules and signals—as key mediators in...